Planta Med 2008; 74(3): 264-266
DOI: 10.1055/s-2008-1034308
Pharmacology
Letter
© Georg Thieme Verlag KG Stuttgart · New York

P-Glycoprotein Inhibitory Activity of Lipophilic Constituents of Echinacea pallida Roots in a Human Proximal Tubular Cell Line

Nadia Romiti1 , Federica Pellati2 , Paola Nieri3 , Stefania Benvenuti2 , Barbara Adinolfi3 , Elisabetta Chieli1
  • 1Department of Experimental Pathology, The School of Medicine, University of Pisa, Pisa, Italy
  • 2Department of Pharmaceutical Sciences, University of Modena and Reggio Emilia, Modena, Italy
  • 3Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy
Further Information

Publication History

Received: September 27, 2007 Revised: December 30, 2007

Accepted: January 14, 2008

Publication Date:
27 February 2008 (online)

Abstract

The n-hexane root extracts from Echinacea pallida, Echinacea angustifolia and Echinacea purpurea were evaluated for inhibition of the multidrug transporter P-glycoprotein (Pgp) activity, the product of the ABCB1 gene, involved in cancer multidrug resistance (MDR) and in herb-drug or drug-drug interactions. The biological assay was performed using the human proximal tubule HK-2 cell line that constitutively expresses ABCB1. The n-hexane extracts of all three species reduced the efflux of the Pgp probe calcein-AM from HK-2 cells two-fold in a concentration-dependent manner, and E. pallida was found to be the most active species. For the first time, two polyacetylenes and three polyenes, isolated from the n-hexane extract of E. pallida roots by a bioassay-guided fractionation, were found to be able to reduce Pgp activity. Pentadeca-(8Z,13Z)-dien-11-yn-2-one was the most efficient compound, being able to decrease the calcein-AM efflux about three-fold with respect to the control at 30 μg/mL.

Abbreviations

Calcein-AM:calcein acetoxymethyl ester

Pgp:P-glycoprotein

References

  • 1 Raskin I, Ribnicky D M, Komarnytsky S, Ilic N, Poulev A, Borisjuk N. et al . Plants and human health in the twenty-first century.  Trends Biotechnol. 2002;  20 522-31.
  • 2 Barnes J, Anderson L A, Gibbons S, Phillipson J D. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacological and clinical properties.  J Pharm Pharmacol. 2005;  57 929-54
  • 3 Woelkart K, Marth E, Suter A, Schoop R, Raggam R B, Koidl C. et al . Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system.  Int J Clin Pharmacol Ther. 2006;  44 401-8
  • 4 Hinz B, Woelkart K, Bauer R. Alkamides from Echinacea inhibit cyclooxygenase-2 activity in human neuroglioma cells.  Biochem Biophys Res Commun. 2007;  360 441-6
  • 5 Woelkart K, Bauer R. The role of alkamides as an active principle of Echinacea. .  Planta Med. 2007;  73 615-23
  • 6 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Carrier J. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.  Clin Pharmacol Ther. 2004;  76 428-40
  • 7 Yale S H, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.  J Altern Complement Med. 2005;  11 433-9
  • 8 Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content.  J Pharm Pharmacol. 2007;  59 567-73
  • 9 O’Connor R. The pharmacology of cancer resistance.  Anticancer Res. 2007;  27 1267-72
  • 10 Tanigawara Y. Role of P-glycoprotein in drug disposition.  Ther Drug Monit. 2000;  22 137-40
  • 11 Zhou S, Lim L Y, Chowbay B. Herbal modulation of P-glycoprotein.  Drug Metab Rev. 2004;  36 57-104
  • 12 Molnar J, Gyemant N, Tanaka M, Hohmann J, Bergmann-Leitner E, Molnar P. et al . Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids.  Curr Pharm Des. 2006;  12 287-311
  • 13 Yu D K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.  J Clin Pharmacol. 1999;  39 1203-11
  • 14 Pellati F, Calo S, Benvenuti S, Adinolfi B, Nieri P, Melegari M. Isolation and structure elucidation of cytotoxic polyacetylenes and polyenes from Echinacea pallida.  Phytochemistry. 2006;  67 1359-64
  • 15 Romiti N, Tramonti G, Chieli E. Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.  Toxicol Appl Pharmacol. 2002;  183 83-91
  • 16 Romiti N, Tramonti G, Donati A, Chieli E. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2.  Life Sci. 2004;  76 293-302
  • 17 Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E. Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells.  Br J Pharmacol. 2006;  148 682-7
  • 18 Hollo Z, Homolya L, Davis C W, Sarkadi B. Calcein accumulation as a fluorimetric functional assay of the multidrug transporter.  Biochim Biophys Acta. 1994;  1191 384-8
  • 19 McDevitt C A, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors?.  Pharmacol Ther. 2007;  113 429-41
  • 20 Raduner S, Bisson W, Abagyan R, Altmann K H, Gertsch J. Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides.  J Nat Prod. 2007;  70 1010-5

Prof. Dr. Elisabetta Chieli

Dipartimento di Patologia Sperimentale

Sezione di Patologia Generale e Clinica

Università degli Studi di Pisa

Scuola Medica

via Roma 55

56126 Pisa

Italy

Phone: +39-050-2218550

Fax: +39-050-2218557

Email: chieli@biomed.unipi.it

    >